Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest BrainCells Inc. Stories

2012-12-05 08:26:31

SAN DIEGO, Nov. 5, 2012 /PRNewswire/ -- BrainCells, Inc. (BCI), a leading biotechnology company developing novel compounds for the treatment of central nervous system (CNS) diseases, announced the successful completion of their Phase 1 multiple ascending dose (MAD) study of BCI-838, the oral prodrug for the company's Group II mGluR2/3 antagonist, BCI-632. BCI will advance the clinical development program of the compound by initiating a Proof-of-Concept (PoC) study in patients with...

2012-02-29 07:00:00

SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- BrainCells Inc., a leading biotechnology company developing novel compounds for the treatment of central nervous system (CNS) diseases, announced today that the Phase 1 single ascending dose (SAD) study of BCI-838 has been successfully completed and that the company has initiated the Phase 1 multiple ascending dose (MAD) study. The SAD study evaluated BCI-838 for safety, tolerability, pharmacokinetics and food effect in healthy male subjects....

2010-08-04 07:00:00

SAN DIEGO, Aug. 4 /PRNewswire/ -- BrainCells Inc. today announced that it has signed an agreement with Proximagen Group to acquire sabcomeline, a clinical-stage muscarinic partial agonist that has potential in the treatment of various psychiatric and neurologic disorders. Under the terms of the agreement, BrainCells will pay Proximagen an upfront fee and development and sales milestone payments together worth up to $51 million, as well as a royalty on sales, for worldwide development and...

2010-04-29 07:00:00

SAN DIEGO, April 29 /PRNewswire/ -- BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary neural stem cell platform technology to identify novel compounds for the treatment of central nervous system (CNS) diseases, announced today that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,678,808 entitled, "5 HT Receptor Mediated Neurogenesis." The patent gives BrainCells coverage for treating depression with...

2009-10-20 07:00:00

SAN DIEGO, Oct. 20 /PRNewswire/ -- BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary neural stem cell platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced the appointment of Drs. Edward Scolnick from the Broad Institute of MIT and Harvard and David Holtzman of Washington University School of Medicine to its scientific advisory board. The appointees join BrainCells' advisory...

2009-07-27 07:00:00

SAN DIEGO, July 27 /PRNewswire/ -- BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced today results from the first clinical proof-of-concept study of BCI-952, a combination of low dose buspirone and melatonin, for the treatment of major depressive disorder (MDD). The data were presented at NCDEU 2009, a meeting co-sponsored by...

2009-03-30 07:00:00

SAN DIEGO, March 30 /PRNewswire/ -- BrainCells Inc. (BCI), a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of neurologic conditions, announced today the appointment of Dr. Philip Jochelson as chief medical officer and Jason Levin as chief business officer. Both have extensive experience in the biopharmaceutical industry with specific expertise in building neurology assets for success. The two will...

2008-12-02 07:00:00

SAN DIEGO, Dec. 2 /PRNewswire/ -- BrainCells Inc. (BCI), a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced today the appointment of David E. Thompson to its board of directors. Thompson is a veteran of the pharmaceutical industry, with a 30-year tenure at Eli Lilly and Co. where he focused on building the company while leading corporate...

2007-09-27 09:00:46

SAN DIEGO and TOKYO, Sept. 27 /PRNewswire/ -- BrainCells Inc. (BCI) and Taisho Pharmaceutical Co., Ltd. (Taisho) today announced that BCI has in-licensed a novel development program from Taisho that BCI will develop for central nervous system (CNS) indications, including mood disorders. Taisho retains rights to the program in Japan and China, while BCI will have rights for the remainder of the world. Financial terms were not disclosed. The licensing agreement follows BCI's determination...